Epilepsia®
Official Journal of the International League Against Epilepsy

Table of Contents

Volume 60, Number 2, February 2019

FULL-LENGTH ORIGINAL RESEARCH

Table of Contents

Volume 60, Number 2, February 2019

FULL-LENGTH ORIGINAL RESEARCH

Epilepsia®
Official Journal of the International League Against Epilepsy

Table of Contents

Volume 60, Number 2, February 2019

FULL-LENGTH ORIGINAL RESEARCH

Table of Contents

Volume 60, Number 2, February 2019

FULL-LENGTH ORIGINAL RESEARCH

Table of Contents

Volume 60, Number 2, February 2019

FULL-LENGTH ORIGINAL RESEARCH

BRIEF COMMUNICATION

Online only: The following articles can be accessed in the electronic version of this issue at onlinelibrary.wiley.com

Using a zebrafish model of Dravet syndrome (DS), we examined the possibility to repurpose some marketed medicines with a serotonergic on- or off-target profile as AED for DS. To examine their potential broader antiseizure profile, we also tested the compounds in a pentylenetetrazol (PTZ) and a treatment-resistant ethyl ketopentenoate (EKP) zebrafish model. Our preclinical results show that lisuride could be a potential candidate for DS treatment. Efavirenz was active in all models, and hence these data are potentially important for future treatment of drug-resistant epilepsy.

Table of Contents

Volume 60, Number 2, February 2019

GRAY MATTERS